These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 1721817)

  • 1. The control of homologous lysis.
    Lachmann PJ
    Immunol Today; 1991 Sep; 12(9):312-5. PubMed ID: 1721817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced reactive lysis of paroxysmal nocturnal hemoglobinuria erythrocytes by C5b-9 does not involve increased C7 binding or cell-bound C3b.
    Rosenfeld SI; Jenkins DE; Leddy JP
    J Immunol; 1985 Jan; 134(1):506-11. PubMed ID: 3964820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of the effects of activation of the alternative pathway of complement on erythrocytes with an isolated deficiency of decay accelerating factor.
    Holguin MH; Martin CB; Bernshaw NJ; Parker CJ
    J Immunol; 1992 Jan; 148(2):498-502. PubMed ID: 1370313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Membrane factors responsible for homologous species restriction of complement-mediated lysis: evidence for a factor other than DAF operating at the stage of C8 and C9.
    Shin ML; Hänsch G; Hu VW; Nicholson-Weller A
    J Immunol; 1986 Mar; 136(5):1777-82. PubMed ID: 2419414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paroxysmal nocturnal hemoglobinuria type III. Lack of an erythrocyte membrane protein restricting the lysis by C5b-9.
    Hänsch GM; Schönermark S; Roelcke D
    J Clin Invest; 1987 Jul; 80(1):7-12. PubMed ID: 3597779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relative roles of decay-accelerating factor, membrane cofactor protein, and CD59 in the protection of human endothelial cells against complement-mediated lysis.
    Brooimans RA; van Wieringen PA; van Es LA; Daha MR
    Eur J Immunol; 1992 Dec; 22(12):3135-40. PubMed ID: 1280224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complement lysis of human erythrocytes. III. Differing effectiveness of human and guinea pig C9 on normal and paroxysmal nocturnal hemoglobinuria cells.
    Rosenfeld SI; Packman CH; Jenkins DE; Countryman JK; Leddy JP
    J Immunol; 1980 Nov; 125(5):2063-8. PubMed ID: 6776186
    [No Abstract]   [Full Text] [Related]  

  • 8. Erythrocytes of patients with paroxysmal nocturnal haemoglobinuria acquire resistance to complement attack by purified 20-kD homologous restriction factor.
    Okada N; Harada R; Okada H
    Clin Exp Immunol; 1990 Apr; 80(1):109-13. PubMed ID: 1691059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complement lysis of human erythrocytes. Differeing susceptibility of two types of paroxysmal nocturnal hemoglobinuria cells to C5b-9.
    Packman CH; Rosenfeld SI; Jenkins DE; Thiem PA; Leddy JP
    J Clin Invest; 1979 Aug; 64(2):428-33. PubMed ID: 457861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of the paroxysmal nocturnal hemoglobinuria phenotype in normal human erythrocytes: effects of 2-aminoethylisothiouronium bromide on membrane proteins that regulate complement.
    Ezzell JL; Wilcox LA; Bernshaw NJ; Parker CJ
    Blood; 1991 Jun; 77(12):2764-73. PubMed ID: 1710519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erythrocyte membrane protein deficiencies in paroxysmal nocturnal hemoglobinuria.
    Schultz DR
    Am J Med; 1989 Sep; 87(3N):22N-29N. PubMed ID: 2484793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implication of membrane factors other than DAF and CD59 in complement-mediated lysis of paroxysmal nocturnal hemoglobinuria erythrocytes.
    Hatanaka M; Inai S; Matsumoto M; Miyagawa S; Masaoka T; Kanamaru A; Kawakita M; Yonemura Y; Sugita Y; Seya T
    Clin Immunol Immunopathol; 1993 Oct; 69(1):52-9. PubMed ID: 7691453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amelioration of lytic abnormalities of paroxysmal nocturnal hemoglobinuria with decay-accelerating factor.
    Medof ME; Kinoshita T; Silber R; Nussenzweig V
    Proc Natl Acad Sci U S A; 1985 May; 82(9):2980-4. PubMed ID: 2581259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant soluble CD59 inhibits reactive haemolysis with complement.
    Sugita Y; Ito K; Shiozuka K; Suzuki H; Gushima H; Tomita M; Masuho Y
    Immunology; 1994 May; 82(1):34-41. PubMed ID: 7519172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paroxysmal nocturnal hemoglobinuria. Enhanced stimulation of platelets by the terminal complement components is related to the lack of C8bp in the membrane.
    Blaas P; Berger B; Weber S; Peter HH; Hänsch GM
    J Immunol; 1988 May; 140(9):3045-51. PubMed ID: 3361126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complement control proteins, CD46, CD55, and CD59, as common surface constituents of human and simian immunodeficiency viruses and possible targets for vaccine protection.
    Montefiori DC; Cornell RJ; Zhou JY; Zhou JT; Hirsch VM; Johnson PR
    Virology; 1994 Nov; 205(1):82-92. PubMed ID: 7526538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of homologous complement by CD59 is mediated by a species-selective recognition conferred through binding to C8 within C5b-8 or C9 within C5b-9.
    Rollins SA; Zhao J; Ninomiya H; Sims PJ
    J Immunol; 1991 Apr; 146(7):2345-51. PubMed ID: 1706395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of the membrane attack complex of complement. Evidence that C8 gamma is not the target of homologous restriction factors.
    Davé SJ; Sodetz JM
    J Immunol; 1990 Apr; 144(8):3087-90. PubMed ID: 2324496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New monoclonal antibodies in CD59: use for the analysis of peripheral blood cells from paroxysmal nocturnal haemoglobinuria (PNH) patients and for the quantitation of CD59 on normal and decay accelerating factor (DAF)-deficient erythrocytes.
    Fletcher A; Bryant JA; Gardner B; Judson PA; Spring FA; Parsons SF; Mallinson G; Anstee DJ
    Immunology; 1992 Mar; 75(3):507-12. PubMed ID: 1374058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of rabbit complement component C8. Functional evidence for the species-selective recognition of C8 alpha by homologous restriction factor (CD59).
    White RV; Kaufman KM; Letson CS; Platteborze PL; Sodetz JM
    J Immunol; 1994 Mar; 152(5):2501-8. PubMed ID: 7510745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.